Abundant Produce adds more talent to its board
Abundant Produce Limited (ASX:ABT) has today announced the appointment of new Board member, Seona Wallace.
Wallace is an established figure within the global skincare and pharmaceutical industry, and is a Board member of the Australian Self Medication Industry (ASMI). It is hoped her over 20 years’ experience and high profile will round out ABT’s already expert management team.
Wallace built her career working in senior commercial roles with multinational pharmaceutical companies including Sanofi and Boehringer Ingelheim. She has been Managing Director of leading healthcare group Health One since April 2015.
With her directorship added to the mix, ABT is in an ideal position to increase its market presence via Wallace’s innovative marketing approach that has seen her become an industry leader in product launches and go-to-market planning.
In addition, the company stated that Wallace would bring a broader range of perspectives to the table as well as increasing gender diversity among the team.
ABT CEO, Tony Crimmins said: “We will benefit greatly from Seona’s appointment to the Board, particularly with her exceptional, results driven track record and her comprehensive and complementary experience across the nutraceutical and skincare areas.
“As Managing Director, Seona has helped to position HealthOne as the fastest growing commercial healthcare partner in Australia. Through our sales, marketing and distribution agreement with HealthOne, we are establishing a foothold in the pharmacy channel with impressive potential for further growth.
“As a research focused company, we will benefit from Ms Wallace’s extensive experience in this area by gaining input at the early product development stage and translating it into a commercial proposition with the introduction of innovative products and sales strategies to ensure optimum results for ABT.”
Wallace also commented on her appointment: “I am thrilled to be joining Abundant at such an exciting time in product development. Launching to consumers in Australia is a huge opportunity to take Abundant to the next level and establish itself as a brand of choice in the pharmacy channel”.
ABT remains a speculative play and as such any investment decision should be made with caution and professional financial advice should be sought.
When the experts at Next Investors have a stock pick, it may pay to listen.
The Next Investors have been investing in ASX small cap stocks for years, with their best small cap picks yielding returns of 1,200%, 1,120%, 900% and 678%.
They have just revealed their hand-picked, FY2021 stock portfolio of high conviction long-term investments.
Click the link below to see what they are currently investing in.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.